CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease

Information

  • Research Project
  • 8311461
  • ApplicationId
    8311461
  • Core Project Number
    R41AG042205
  • Full Project Number
    1R41AG042205-01
  • Serial Number
    042205
  • FOA Number
    PA-11-097
  • Sub Project Id
  • Project Start Date
    9/1/2012 - 12 years ago
  • Project End Date
    8/31/2013 - 11 years ago
  • Program Officer Name
    HSIAO, JOHN
  • Budget Start Date
    9/1/2012 - 12 years ago
  • Budget End Date
    8/31/2013 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/22/2012 - 12 years ago

CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease

DESCRIPTION (provided by applicant): Research & Related Other Project Information Item 7. Project Summary/Abstract Neurodegeneration in Alzheimer's disease (AD) may result from deposition of A¿ as plaques in brain tissue. However, less effort has been made to elucidate the role of tau- containing neurofibrillary tangles (NFTs) in AD. Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neurodegenerative diseases. In this proposal the tau pathway is targeted through inhibition of the molecular chaperone Hsp90 as a promising new approach to affect the disease progression of AD. The goal of this grant is to optimize two structurally distinct scaffolds aided by in silico modeling and physical-chemical property predictions in order to generate novel brain permeable Hsp90 inhibitors as AD therapeutics. Subsequently, these compounds will be clinically developed for the treatment of AD using CSF biomarkers, as well as improved cognition, for in vivo efficacy determinations. PUBLIC HEALTH RELEVANCE: Research & Related Other Project Information Item 8. Project Narrative This research is focused on identifying potential drug candidates to treat Alzheimer's disease (AD) and in this way it addresses NIA's priorities to support research on health and disease in the aged. Furthermore, this project targets the tau pathway as a promising new approach to affect the disease progression of AD.

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R41
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    200752
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    866
  • Ed Inst. Type
  • Funding ICs
    NIA:200752\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    YUMA THERAPEUTICS CORPORATION
  • Organization Department
  • Organization DUNS
    831491571
  • Organization City
    Cambridge
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021402808
  • Organization District
    UNITED STATES